Timing of Chemotherapy for Glioblastoma May Matter
WEDNESDAY, April 21, 2021 -- Chemotherapy for glioblastoma (GBM) may work better in the morning, according to a study recently published online in Neuro-Oncology Advances.
Anna R. Damato, from the Washington University School of Medicine in St. Louis, and colleagues assessed whether timing of maintenance temozolomide (TMZ) administration affects GBM patient outcome. The analysis included 166 patients with newly diagnosed GBM from 2010 through 2018, who had surgery, had chemoradiation, and were prescribed TMZ for either the morning or evening. Patients were followed for a median of 5.07 years.
The researchers found that patients taking TMZ in the morning showed longer overall survival (OS) compared with those taking TMZ in the evening (median OS, 1.43 versus 1.13 years) with a significant year 1 restricted mean survival time difference (RMST; −0.09). In an analysis of O6-methylguanine-DNA-methyltransferase-methylated patients, median OS was six months longer for patients taking TMZ in the morning, with significant RMST differences at years 1 to 2.5. Among all patients, superiority of morning TMZ at years 1, 2, and 5 was supported by RMST difference regression in an adjusted analysis.
"Many oncologists give it in the evening because patients tend to report fewer side effects then," a coauthor said in a statement. "We saw that in our study as well. But it could be that the increased side effects -- which we can manage with other therapies -- are a sign that the drug is working more effectively."
© 2021 HealthDay. All rights reserved.
Posted: April 2021
Read this next
FRIDAY, May 14, 2021 -- A mysterious illness that caused brain injuries to more than 130 spies, diplomats, soldiers, and other U.S. personnel overseas during the past few years is...
THURSDAY, May 13, 2021 -- The federal government is providing $7.4 billion to hire more school nurses to vaccinate children, to create a service corps for health care, and to...
THURSDAY, May 13, 2021 -- An artificial intelligence (AI) system can predict deterioration of COVID-19 patients in the emergency department, according to a study published online...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.